#United States #Denver #Kidney Care #Fresenius Medical Care #multiFiltratePRO

Fresenius Medical Care Revolutionizes Kidney Treatment with multiFiltratePRO Launch

In a groundbreaking move for renal care, Fresenius Medical Care has officially launched its multiFiltratePRO system in the United States. As a crucial advancement for critically ill patients suffering from acute kidney injury (AKI), this innovative system is set to transform the landscape of kidney replacement therapies in the critical care environment.

Key Features of multiFiltratePRO

The multiFiltratePRO system integrates sophisticated technology designed to simplify complex treatment procedures. A defining characteristic of this system is its elimination of separate citrate and calcium pumps. This enhancement allows it to automatically adjust treatment parameters in response to changing clinical conditions, thus alleviating the complexity that often challenges hospital intensive care teams.

On October 19, 2026, the U.S. Food and Drug Administration (FDA) granted clearance for the multiFiltratePRO system and its dedicated solutions, namely Cienby™ (sodium citrate solution) and Calrezdy™ (calcium chloride solution). This marks a significant milestone as it is the first continuous kidney replacement therapy (CKRT) system approved in the U.S. that employs the Ci-Ca protocol for regional citrate anticoagulation (RCA).

Cienby serves as an anticoagulant during procedures like continuous venovenous hemodialysis (CVVHD) and continuous venovenous hemodiafiltration (CVVHDF) for adult and pediatric patients weighing over 40 kg. Calrezdy provides essential calcium substitution during these processes. These innovations are particularly crucial for effective management of AKI, where timely and efficient kidney function support can significantly influence patient outcomes.

The Importance of Innovative Kidney Care Solutions

Fresenius Medical Care has a rich history of identifying and developing innovative treatment solutions tailored to the specific needs of patients. The launch of multiFiltratePRO underscores this commitment as it introduces a level of sophistication and efficiency not previously available in the U.S. market. The company previously made strides with the introduction of the 5008X™ CAREsystem, which brought hemodiafiltration techniques to American health care providers, a standard practice in Europe and Asia-Pacific.

The integration of the Ci-Ca protocol with the multiFiltratePRO system is essential for effectively managing anticoagulation during continuous renal replacement therapy. With this protocol, citrate and calcium infusion rates adjust automatically based on blood flow changes, allowing clinicians to maintain the necessary protocol-defined ratios. Minimizing clotting during these treatments is critical, particularly in critical care settings where every minute counts in providing effective kidney support to severely ill patients.

Feedback from Fresenius Medical Care Leadership

Joe Turk, Chief Executive Officer of Care Enablement at Fresenius Medical Care, expressed his enthusiasm about the launch: "We have a long history of bringing innovative kidney care solutions to patients globally and making them accessible in new markets. The introduction of multiFiltratePRO with the Ci-Ca Protocol illustrates that commitment. It enhances the array of options available for critical care professionals while reinforcing our leadership in advancing kidney care innovation."

Launch Events and Future Availability

Fresenius Medical Care plans to showcase the multiFiltratePRO system at the ASN Kidney Week 2026, held in Denver. Attendees will have the opportunity to interact with product experts and see firsthand how this system supports critically ill patients battling acute kidney injuries. Following the initial controlled launch, the company anticipates rolling out the system more widely across healthcare settings in the United States.

Conclusion

The U.S. launch of the multiFiltratePRO system by Fresenius Medical Care represents a significant leap forward in kidney care technology, aimed to enhance treatment effectiveness for intensive care unit patients struggling with acute kidney injury. This advancement not only offers efficient treatment solutions but also aligns with the ongoing efforts to improve patient outcomes in critical care settings. Fresenius continues to set the bar high, reflecting its dedication to kidney care innovation worldwide.